Leerink Swann Downgrades Alere (ALR) to Market Perform
Tweet
Share
E-mailGet Alerts ALR Hot Sheet
Price: $1.32 --0%
Rating Summary:
6 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Rating Summary:
6 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Join SI Premium – FREE
Leerink Swann downgraded Alere (NYSE: ALR) from Outperform to Market Perform, price target range cut to $19-20.
Analyst, Dan Leonard, said, "We’ve reduced our estimates to reflect an assumption that the outcome of ALR’s FDA inspection could result in a $0.20 annual detriment to EPS (though outcome is highly uncertain, and range could be $0.14 to $0.39, in our view). The primary pillars of our prior Outperform thesis (upside to numbers and upside to sentiment) no longer hold. While we already knew an FDA inspection was ongoing, the revenue magnitude of products exposed is ~2x our prior expectation, and the subpoena from the Office of Inspector General of the Department of Health and Human Services could complicate matters further. Thus, we have reduced our valuation to a range to $19 - $20 and downgrade the stock."
FY12 EPS estimate cut from $2.75 to $2.55 and FY13 from $2.74 to $2.54.
For an analyst ratings summary and ratings history on Alere click here. For more ratings news on Alere click here.
Shares of Alere closed at $22.30 yesterday.
Analyst, Dan Leonard, said, "We’ve reduced our estimates to reflect an assumption that the outcome of ALR’s FDA inspection could result in a $0.20 annual detriment to EPS (though outcome is highly uncertain, and range could be $0.14 to $0.39, in our view). The primary pillars of our prior Outperform thesis (upside to numbers and upside to sentiment) no longer hold. While we already knew an FDA inspection was ongoing, the revenue magnitude of products exposed is ~2x our prior expectation, and the subpoena from the Office of Inspector General of the Department of Health and Human Services could complicate matters further. Thus, we have reduced our valuation to a range to $19 - $20 and downgrade the stock."
FY12 EPS estimate cut from $2.75 to $2.55 and FY13 from $2.74 to $2.54.
For an analyst ratings summary and ratings history on Alere click here. For more ratings news on Alere click here.
Shares of Alere closed at $22.30 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Upgrades Bharat Forge Ltd. (BHFC:IN) to Buy
- Deutsche Boerse AG (DB1:GR) (DBOEY) PT Lowered to EUR193 at JPMorgan
- Jefferies Downgrades LTIMindtree Ltd (LTIM:IN) to Underperform
Create E-mail Alert Related Categories
Analyst EPS Change, Analyst EPS View, Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
